Format

Send to

Choose Destination
See comment in PubMed Commons below
Mol Ther Nucleic Acids. 2014 Jul 8;3:e174. doi: 10.1038/mtna.2014.23.

A short antisense oligonucleotide ameliorates symptoms of severe mouse models of spinal muscular atrophy.

Author information

1
1] Department of Pediatrics, Feinberg School of Medicine, Northwestern University, Illinois, Chicago, Illinois, USA [2] Human Molecular Genetics Program, Stanley Manne Children's Research Institute at Ann & Robert H. Lurie Children's Hospital, Chicago, Illinois, USA.
2
Department of Biomedical Sciences, Iowa State University, Ames, Iowa, USA.

Abstract

Recent reports underscore the unparalleled potential of antisense-oligonucleotide (ASO)-based approaches to ameliorate various pathological conditions. However, in vivo studies validating the effectiveness of a short ASO (<10-mer) in the context of a human disease have not been performed. One disease with proven amenability to ASO-based therapy is spinal muscular atrophy (SMA). SMA is a neuromuscular disease caused by loss-of-function mutations in the survival motor neuron 1 (SMN1) gene. Correction of aberrant splicing of the remaining paralog, SMN2, can rescue mouse models of SMA. Here, we report the therapeutic efficacy of an 8-mer ASO (3UP8i) in two severe models of SMA. While 3UP8i modestly improved survival and function in the more severe Taiwanese SMA model, it dramatically increased survival, improved neuromuscular junction pathology, and tempered cardiac deficits in a new, less severe model of SMA. Our results expand the repertoire of ASO-based compounds for SMA therapy, and for the first time, demonstrate the in vivo efficacy of a short ASO in the context of a human disease.

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center